ArticleFrontiers in endocrinology2021
Large-Volume Lateral Lymph Node Metastasis Predicts Worse Prognosis in Papillary Thyroid Carcinoma Patients With N1b.
Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Article
- ATA 2015-2025 risk stratification transition: prognostic significance of N1b disease in papillary thyroid carcinoma with limited nodal burden.The oncologist · 2026Article
- Predictors of false-negative serum thyroglobulin in persistent/recurrent Papillary Thyroid Carcinoma cervical lymph nodes.Frontiers in oncology · 2026Article
- The development and validation of a machine learning algorithm for identifying lateral lymph nodes skip metastasis in papillary thyroid cancer.Frontiers in oncology · 2026Article
- Clinicopathological predictors of right para esophageal lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis.World journal of clinical oncology · 2025Article
- Development and validation of a nomogram to predict failure of initial radioactive iodine therapy in differentiated thyroid cancer: a retrospective cohort study.Scientific reports · 2025Article
- A predictive model using platelets and neutrophil-to-lymphocyte ratio for the number of lymph node metastases in papillary thyroid carcinoma: a retrospective analysis.Gland surgery · 2025Article
- High GOLT1A expression induces poor prognosis in papillary thyroid carcinoma.Scientific reports · 2025Article
- Article
- Risk factors for cervical lymph node metastasis at different lateral levels in papillary thyroid cancer: level III as the central hub.Gland surgery · 2024Article
- Prediction of lateral lymph node metastasis with short diameter less than 8 mm in papillary thyroid carcinoma based on radiomics.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Role of ultrasound‑guided fine‑needle aspiration cytology combined with thyroid peroxidase and thyroglobulin antibodies in evaluating cervical lymph node metastasis in thyroid cancer.Oncology letters · 2024Article
- Classification of superficial suspected lymph nodes: non-invasive radiomic model based on multiphase contrast-enhanced ultrasound for therapeutic options of lymphadenopathy.Quantitative imaging in medicine and surgery · 2024Article
- Risk factors for cervical lymph node metastasis of papillary thyroid cancer in elderly patients aged 65 and older.Frontiers in endocrinology · 2024Article
- Nomogram for preoperative estimation risk of lateral cervical lymph node metastasis in papillary thyroid carcinoma: a multicenter study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- The optimal extent of lymph node dissection in N1b papillary thyroid microcarcinoma based on clinicopathological factors and preoperative ultrasonography.Gland surgery · 2022Article
- Machine learning-based dynamic prediction of lateral lymph node metastasis in patients with papillary thyroid cancer.Frontiers in endocrinology · 2022Article
- Integrated analysis of fibroblasts molecular features in papillary thyroid cancer combining single-cell and bulk RNA sequencing technology.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to evaluate the relevance of large-volume lateral lymph node metastases (LLNMs) at risk of recurrence/persistence in papillary thyroid carcinoma (PTC) with LLNMs (N1b). This retrospective study included 448 PTC patients, who had positive LLNMs confirmed by histology and suspected of LLNMs by preoperative ultrasound. According to the number of pathological LLNMs, patients were divided into large-volume LLNM (number of LLNMs >5) and low-volume LLNM (number of LLNMs ≤5). Risk factors of recurrence/persistence in PTC patients with N1b were analyzed. Preoperative ultrasound features of PTC with large-volume LLNM were analyzed. For the patients with a mean follow-up of 44.0 months, the risk of recurrence/persistence was 25.1% in PTC patients with N1b. The recurrence/persistence rate was significantly higher in patients with large-volume LLNM than in patients with low-volume LLNM by multivariate analysis (37.3% vs. 17.1%; HR = 2.451, 95% CI 1.41-4.261, p = 0.001). The 3-year and 5-year recurrence/persistence-free survival for those with large-volume LLNM were 93.2% and 47.2%, respectively. Moreover, we found that multilevel suspected LLNMs and loss of fatty hilum were independent preoperative indicative factors of large-volume LLNM (OR = 6.239, 95% CI 3.547-10.977, p < 0.001; OR = 5.149, 95% CI 1.859-14.261, p = 0.002). In conclusion, multilevel suspected LLNM and loss of fatty hilum on ultrasound tended to be more common in patients with large-volume LLNM. PTC patients with large-volume LLNM are at a higher recurrent/persistent risk than those with low-volume LLNM. Large-volume LLNM may be used to stratify the risk of recurrence/persistence in PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.